CD274 and non-small cell lung carcinoma: The recent launch of an anti-PD-L1 antibody has represented a significant breakthrough for patients with advanced solid tumors.4 Strikingly, blockade of PD-L1 induced durable tumor regression and prolonged disease stabilization in patients with advanced NSCLC.